Across TCGA pan-cancer cohorts, RSC1A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated RSC1A1 data layer compared with 1 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RSC1A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RSC1A1 expression acts as an unfavorable survival marker.

OV, LIHC, and LUAD are the cancer types where RSC1A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
LIHC	DFS	Median	All	0.106	0.530	.002	15	view →
LUAD	OS	Median	III,IV	0.158	0.663	.008	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RSC1A1 tumor-vs-normal RNA expression · all RSC1A1 data types